EpiEP develops cardiac devices, which enable physicians to operate on the surface of the heart with a minimally invasive approach for the treatment of arrhythmias such as Atrial Fibrillation and Ventricular Tachycardia. The first product, the EpiAccess System has been utilized in pre-clinical and clinical trials to date and the first regulatory milestone has been reached with submission of the technical design dossier for CE Mark. The next significant regulatory submission will occur for FDA 510(k) clearance in early 2014.


Back to Companies